Amelia Gilio

Amelia Gilio is a Postdoctoral Fellow at Pfizer, working in the Biocatalysis Center of Emphasis.2 Her research interests focus on protein engineering and structural studies of enzymes.2

Background and Education

Prior to her current role at Pfizer, Amelia completed her PhD as a student in the Grogan Group at YSBL_York (York Structural Biology Laboratory at the University of York).3 During her doctoral studies, she was funded by Pfizer and studied imine reductases to explore greener routes for producing chiral amines.3

Research Focus

Amelia's work primarily revolves around enzymes involved in reductive amination reactions, particularly:

1. Imine reductases (IREDs)
2. Reductive aminases (RedAms)

These enzymes are NADPH-dependent oxidoreductases that catalyze C–N redox reactions.4 Her research contributes to the development of biocatalytic methods for chiral amine production, which is crucial for the pharmaceutical industry.1

Recent Work

In January 2023, Amelia was involved in a study that demonstrated how a reductive aminase can switch to imine reductase activity for a bulky substrate.5 This research highlights her ongoing contributions to the field of biocatalysis and enzyme engineering.

Amelia's work aligns with the growing interest in developing more sustainable routes to bioactive molecules in the chemical industry.1 Her expertise in enzyme engineering and structural studies positions her at the forefront of efforts to improve biocatalytic processes for pharmaceutical applications.